bearish
Sihuan Pharmaceutical Hldgs
Sihuan Pharmaceutical (460.HK) - The Dispute with CBC Group, the Business and the Outlook
This article mainly analyzed the dispute between Sihuan and CBC Group, the potential impact of the Hugel Acquisition, Sihuan's medical beauty business and other segments performance and the outlook.
Equity Bottom-Up
229 Views, 05 Oct 2021 09:03
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Data & News
- Events & Webinars
Trusted by:
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in ...
Price Chart(Sign Up to Access)
x